Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

TORRANCE, Calif.: TORRANCE, Calif., Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain approved a Temporary License...

Click to view original post